Loading clinical trials...
Loading clinical trials...
Efficacy, Safety, Tolerability, Immunogenicity and Pharmacokinetic Evaluation of HYQVIA in Pediatric Subjects With Primary Immunodeficiency Diseases
Conditions
Interventions
HYQVIA
Locations
19
United States
University of Alabama Medical Center
Birmingham, Alabama, United States
Connecticut Children's Medical Center
Hartford, Connecticut, United States
University of Miami Pediatric Allergy and Immunology
Miami, Florida, United States
University of South Florida Physician Group
St. Petersburg, Florida, United States
Georgia Pollens Clinical Research Centers, Inc.
Albany, Georgia, United States
Emory Healthcare
Atlanta, Georgia, United States
Start Date
September 25, 2017
Primary Completion Date
July 20, 2022
Completion Date
July 20, 2022
Last Updated
October 23, 2023
NCT05755035
NCT01218438
NCT00814320
NCT01175213
Lead Sponsor
Baxalta now part of Shire
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions